Preventing and Treating Anthracycline Cardiotoxicity: New Insights

Konrad Teodor Sawicki, Valentina Sala, Lorenzo Prever, Emilio Hirsch, Hossein Ardehali, Alessandra Ghigo

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Anthracyclines are the cornerstone of many chemotherapy regimens for a variety of cancers. Unfortunately, their use is limited by a cumulative dose-dependent cardiotoxicity. Despite more than five decades of research, the biological mechanisms underlying anthracycline cardiotoxicity are not completely understood. In this review, we discuss the incidence, risk factors, types, and pathophysiology of anthracycline cardiotoxicity, as well as methods to prevent and treat this condition. We also summarize and discuss advances made in the last decade in the comprehension of the molecular mechanisms underlying the pathology.

Original languageEnglish (US)
Pages (from-to)309-332
Number of pages24
JournalAnnual Review of Pharmacology and Toxicology
StatePublished - Jan 6 2021


  • Anthracyclines
  • cardiotoxicity
  • doxorubicin
  • heart failure
  • left ventricular dysfunction
  • oxidative stress

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology


Dive into the research topics of 'Preventing and Treating Anthracycline Cardiotoxicity: New Insights'. Together they form a unique fingerprint.

Cite this